NL-OMON38131CompletedNot Applicable
Betacel dysfunction induced by impaired pancreas anatomy and insulin sensitivity in subjects with heterozygous EXT1 or EXT2 Mutations - BEEM-2
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Caucasian subjects (male/female), aged between 18-65 years of age with heterozygous EXT-1 or EXT-2 mutations as well as unaffected related controls matched for age and gender and subjects wiht known type 2 diabetes mellitus.
Exclusion Criteria
- •claustrophobia, pregnant subjects or female participant at childbearing age not using adequate anticonception, renal dysfunction during screening, exogenous insulin use.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects; A 52-week randomized controlled factorial study in subjects with impaired fasting glucose and/or impaired glucose tolerance - PRESERVEEUCTR2006-003483-59-NLVU University Medical Centre
Completed
Not Applicable
Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects: a 52-week randomised controlled factorial study in subjects with impaired fasting glucose and/or impaired glucose toleranceImpaired glucose metabolismNutritional, Metabolic, EndocrineISRCTN42786336VU University Medical Center (The Netherlands)144
Completed
Not Applicable
PRESERVE TRIAL:Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects. A 52-week randomized controlled factorial study in subjects with IFG and/or IGT.Amendment 2007: PancREatic beta-cell dySfunction rEstoRed by Valsartan Effects – PRESERVE Study.Amendment 2007: In stead of two medicaments (Rosiglitazon and valsartan), only valsartan has been completed. Due to negative publicity, Rosiglitazon was stopped. Target number of participant is thereby decreased from 144Type 2 diabetes mellitus, impaired glucose metabolismNL-OMON23620VU University Medical Center,AmsterdamThe Netherlands80
Not yet recruiting
Not Applicable
Impact of exocrine insufficiency of pancreas and supplementation of pancreatic digestive enzymes on nonalcoholic fatty liver disease (REMOTE study)Before starting enrollmentJPRN-UMIN000026825onuma Institute of Community Medicine, Niigata Medical and Dental Hospital60
Recruiting
Not Applicable
Study to determine the relative level of insulin resistance and defect in insulin secretion in diabetic patients of different body habitus.CTRI/2022/02/040316Dr Sarin S M